http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 27 Aug 2026 07:08:50 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Analyst+Comments/H.C.+Wainwright+Reiterates+Buy+Rating+on+Voyager+Therapeutics+%28VYGR%29/26984621.html <p>H.C. Wainwright analyst Patrick R. Trucchio reiterated a Buy rating and $25.00 price target on Voyager Therapeutics (NASDAQ: VYGR).</p><p>The analyst commented: "On August 21, we hosted an H.C. Wainwright At Home virtual fireside chat with Voyager Therapeutics' Chief Executive Officer Alfred Sandrock, covering the two wholly owned tau programs in Alzheimer's disease, the TRACER capsid and ALPL NeuroShuttle platforms, the partnered portfolio, and business development strategy. Both wholly owned programs are on track for 4Q26 inflection: tau positron emission tomography (PET) imaging efficacy data from the fully enrolled 52-patient Phase 1 multiple ascending dose (MAD) trial evaluating the anti-tau antibody http://www.streetinsider.com/Analyst+Comments/H.C.+Wainwright+Reiterates+Buy+Rating+on+Voyager+Therapeutics+%28VYGR%29/26984621.html Thu, 27 Aug 2026 07:08:50 -0400 VYGR http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Voyager+Therapeutics%2C++++++++++++++++++Filed+by%3A+ARMISTICE+CAPITAL%2C+LLC/26926474.html si-local-file:///var/storage/secattach/20260814/26926474.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Voyager+Therapeutics%2C++++++++++++++++++Filed+by%3A+ARMISTICE+CAPITAL%2C+LLC/26926474.html Fri, 14 Aug 2026 10:30:00 -0400 O.17919569 VYGR http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Voyager+Therapeutics%2C++++++++++++++++++Filed+by%3A+ARMISTICE+CAPITAL%2C+LLC/26926474.html si-local-file:///var/storage/secattach/20260814/26926474.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Voyager+Therapeutics%2C++++++++++++++++++Filed+by%3A+ARMISTICE+CAPITAL%2C+LLC/26926474.html Fri, 14 Aug 2026 10:30:00 -0400 O.17919569 VYGR http://www.streetinsider.com/Earnings/Voyager+Therapeutics+%28VYGR%29+Tops+Q2+EPS+by+10c/26885738.html <p>Voyager Therapeutics (NASDAQ: VYGR) reported Q2 EPS of ($0.40), $0.10 better than the analyst estimate of ($0.50). Revenue for the quarter came in at $3.17 million versus the consensus estimate of $4.74 million.</p><p>For earnings history and earnings-related data on Voyager Therapeutics (VYGR) <a href="http://www.streetinsider.com/ec_earnings.php?q=VYGR">click here</a>.</p> http://www.streetinsider.com/Earnings/Voyager+Therapeutics+%28VYGR%29+Tops+Q2+EPS+by+10c/26885738.html Thu, 06 Aug 2026 17:34:22 -0400 VYGR http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Voyager+Therapeutics%2C+++++For%3A+Aug+06/26883403.html si-local-file:///var/storage/secattach/20260806/26883403.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Voyager+Therapeutics%2C+++++For%3A+Aug+06/26883403.html Thu, 06 Aug 2026 16:04:00 -0400 O.17919569 VYGR http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Voyager+Therapeutics%2C+++++For%3A+Aug+06/26883403.html si-local-file:///var/storage/secattach/20260806/26883403.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Voyager+Therapeutics%2C+++++For%3A+Aug+06/26883403.html Thu, 06 Aug 2026 16:04:00 -0400 O.17919569 VYGR http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Voyager+Therapeutics%2C+++++For%3A+Jun+30/26883336.html si-local-file:///var/storage/secattach/20260806/26883336.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Voyager+Therapeutics%2C+++++For%3A+Jun+30/26883336.html Thu, 06 Aug 2026 16:02:00 -0400 O.17919569 VYGR http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Voyager+Therapeutics%2C+++++For%3A+Jun+30/26883336.html si-local-file:///var/storage/secattach/20260806/26883336.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Voyager+Therapeutics%2C+++++For%3A+Jun+30/26883336.html Thu, 06 Aug 2026 16:02:00 -0400 O.17919569 VYGR http://www.streetinsider.com/Press+Releases/Voyager+Reports+Second+Quarter+2026+Financial+and+Operating+Results/26883252.html <p align="center"><em>- VY7523 clinical data and VY1706 clinical entry, both in Alzheimer’s, expected Q4 2026 -</em></p> <p align="center"><em>- Ended Q2 2026 with cash position of $149 million, runway into 2028 -</em></p> <p>LEXINGTON, Mass., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today reported second quarter 2026 financial and operating results.</p> <p>“We view tau as a critical disease-modifying target in Alzheimer’s disease, and we believe recent third-party data validate this hypothesis,” said Alfred W. Sandrock, Jr., M.D., Ph.D., Chief Executive Officer of Voyager. http://www.streetinsider.com/Press+Releases/Voyager+Reports+Second+Quarter+2026+Financial+and+Operating+Results/26883252.html Thu, 06 Aug 2026 16:01:00 -0400 A.00556501 A.06822034 A.09642568 A.17150087 O.00222524 O.17919569 O.20026344 O.20371933 O.34929518 VYGR http://www.streetinsider.com/Press+Releases/Voyager+Reports+Second+Quarter+2026+Financial+and+Operating+Results/26883252.html <p align="center"><em>- VY7523 clinical data and VY1706 clinical entry, both in Alzheimer’s, expected Q4 2026 -</em></p> <p align="center"><em>- Ended Q2 2026 with cash position of $149 million, runway into 2028 -</em></p> <p>LEXINGTON, Mass., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today reported second quarter 2026 financial and operating results.</p> <p>“We view tau as a critical disease-modifying target in Alzheimer’s disease, and we believe recent third-party data validate this hypothesis,” said Alfred W. Sandrock, Jr., M.D., Ph.D., Chief Executive Officer of Voyager. http://www.streetinsider.com/Press+Releases/Voyager+Reports+Second+Quarter+2026+Financial+and+Operating+Results/26883252.html Thu, 06 Aug 2026 16:01:00 -0400 A.00556501 A.06822034 A.09642568 A.17150087 O.00222524 O.17919569 O.20026344 O.20371933 O.34929518 VYGR http://www.streetinsider.com/Press+Releases/Voyager+Reports+Second+Quarter+2026+Financial+and+Operating+Results/26883252.html <p align="center"><em>- VY7523 clinical data and VY1706 clinical entry, both in Alzheimer’s, expected Q4 2026 -</em></p> <p align="center"><em>- Ended Q2 2026 with cash position of $149 million, runway into 2028 -</em></p> <p>LEXINGTON, Mass., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today reported second quarter 2026 financial and operating results.</p> <p>“We view tau as a critical disease-modifying target in Alzheimer’s disease, and we believe recent third-party data validate this hypothesis,” said Alfred W. Sandrock, Jr., M.D., Ph.D., Chief Executive Officer of Voyager. http://www.streetinsider.com/Press+Releases/Voyager+Reports+Second+Quarter+2026+Financial+and+Operating+Results/26883252.html Thu, 06 Aug 2026 16:01:00 -0400 A.00556501 A.06822034 A.09642568 A.17150087 O.00222524 O.17919569 O.20026344 O.20371933 O.34929518 VYGR http://www.streetinsider.com/Press+Releases/Voyager+Reports+Second+Quarter+2026+Financial+and+Operating+Results/26883252.html <p align="center"><em>- VY7523 clinical data and VY1706 clinical entry, both in Alzheimer’s, expected Q4 2026 -</em></p> <p align="center"><em>- Ended Q2 2026 with cash position of $149 million, runway into 2028 -</em></p> <p>LEXINGTON, Mass., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today reported second quarter 2026 financial and operating results.</p> <p>“We view tau as a critical disease-modifying target in Alzheimer’s disease, and we believe recent third-party data validate this hypothesis,” said Alfred W. Sandrock, Jr., M.D., Ph.D., Chief Executive Officer of Voyager. http://www.streetinsider.com/Press+Releases/Voyager+Reports+Second+Quarter+2026+Financial+and+Operating+Results/26883252.html Thu, 06 Aug 2026 16:01:00 -0400 A.00556501 A.06822034 A.09642568 A.17150087 O.00222524 O.17919569 O.20026344 O.20371933 O.34929518 VYGR http://www.streetinsider.com/Press+Releases/Voyager+Reports+Second+Quarter+2026+Financial+and+Operating+Results/26883252.html <p align="center"><em>- VY7523 clinical data and VY1706 clinical entry, both in Alzheimer’s, expected Q4 2026 -</em></p> <p align="center"><em>- Ended Q2 2026 with cash position of $149 million, runway into 2028 -</em></p> <p>LEXINGTON, Mass., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today reported second quarter 2026 financial and operating results.</p> <p>“We view tau as a critical disease-modifying target in Alzheimer’s disease, and we believe recent third-party data validate this hypothesis,” said Alfred W. Sandrock, Jr., M.D., Ph.D., Chief Executive Officer of Voyager. http://www.streetinsider.com/Press+Releases/Voyager+Reports+Second+Quarter+2026+Financial+and+Operating+Results/26883252.html Thu, 06 Aug 2026 16:01:00 -0400 A.00556501 A.06822034 A.09642568 A.17150087 O.00222524 O.17919569 O.20026344 O.20371933 O.34929518 VYGR http://www.streetinsider.com/Press+Releases/Voyager+Reports+Second+Quarter+2026+Financial+and+Operating+Results/26883252.html <p align="center"><em>- VY7523 clinical data and VY1706 clinical entry, both in Alzheimer’s, expected Q4 2026 -</em></p> <p align="center"><em>- Ended Q2 2026 with cash position of $149 million, runway into 2028 -</em></p> <p>LEXINGTON, Mass., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today reported second quarter 2026 financial and operating results.</p> <p>“We view tau as a critical disease-modifying target in Alzheimer’s disease, and we believe recent third-party data validate this hypothesis,” said Alfred W. Sandrock, Jr., M.D., Ph.D., Chief Executive Officer of Voyager. http://www.streetinsider.com/Press+Releases/Voyager+Reports+Second+Quarter+2026+Financial+and+Operating+Results/26883252.html Thu, 06 Aug 2026 16:01:00 -0400 A.00556501 A.06822034 A.09642568 A.17150087 O.00222524 O.17919569 O.20026344 O.20371933 O.34929518 VYGR http://www.streetinsider.com/Press+Releases/Voyager+Reports+Second+Quarter+2026+Financial+and+Operating+Results/26883252.html <p align="center"><em>- VY7523 clinical data and VY1706 clinical entry, both in Alzheimer’s, expected Q4 2026 -</em></p> <p align="center"><em>- Ended Q2 2026 with cash position of $149 million, runway into 2028 -</em></p> <p>LEXINGTON, Mass., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today reported second quarter 2026 financial and operating results.</p> <p>“We view tau as a critical disease-modifying target in Alzheimer’s disease, and we believe recent third-party data validate this hypothesis,” said Alfred W. Sandrock, Jr., M.D., Ph.D., Chief Executive Officer of Voyager. http://www.streetinsider.com/Press+Releases/Voyager+Reports+Second+Quarter+2026+Financial+and+Operating+Results/26883252.html Thu, 06 Aug 2026 16:01:00 -0400 A.00556501 A.06822034 A.09642568 A.17150087 O.00222524 O.17919569 O.20026344 O.20371933 O.34929518 VYGR http://www.streetinsider.com/Press+Releases/Voyager+Reports+Second+Quarter+2026+Financial+and+Operating+Results/26883252.html <p align="center"><em>- VY7523 clinical data and VY1706 clinical entry, both in Alzheimer’s, expected Q4 2026 -</em></p> <p align="center"><em>- Ended Q2 2026 with cash position of $149 million, runway into 2028 -</em></p> <p>LEXINGTON, Mass., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today reported second quarter 2026 financial and operating results.</p> <p>“We view tau as a critical disease-modifying target in Alzheimer’s disease, and we believe recent third-party data validate this hypothesis,” said Alfred W. Sandrock, Jr., M.D., Ph.D., Chief Executive Officer of Voyager. http://www.streetinsider.com/Press+Releases/Voyager+Reports+Second+Quarter+2026+Financial+and+Operating+Results/26883252.html Thu, 06 Aug 2026 16:01:00 -0400 A.00556501 A.06822034 A.09642568 A.17150087 O.00222524 O.17919569 O.20026344 O.20371933 O.34929518 VYGR http://www.streetinsider.com/Press+Releases/Voyager+Reports+Second+Quarter+2026+Financial+and+Operating+Results/26883252.html <p align="center"><em>- VY7523 clinical data and VY1706 clinical entry, both in Alzheimer’s, expected Q4 2026 -</em></p> <p align="center"><em>- Ended Q2 2026 with cash position of $149 million, runway into 2028 -</em></p> <p>LEXINGTON, Mass., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today reported second quarter 2026 financial and operating results.</p> <p>“We view tau as a critical disease-modifying target in Alzheimer’s disease, and we believe recent third-party data validate this hypothesis,” said Alfred W. Sandrock, Jr., M.D., Ph.D., Chief Executive Officer of Voyager. http://www.streetinsider.com/Press+Releases/Voyager+Reports+Second+Quarter+2026+Financial+and+Operating+Results/26883252.html Thu, 06 Aug 2026 16:01:00 -0400 A.00556501 A.06822034 A.09642568 A.17150087 O.00222524 O.17919569 O.20026344 O.20371933 O.34929518 VYGR http://www.streetinsider.com/Press+Releases/Voyager+Reports+Second+Quarter+2026+Financial+and+Operating+Results/26883252.html <p align="center"><em>- VY7523 clinical data and VY1706 clinical entry, both in Alzheimer’s, expected Q4 2026 -</em></p> <p align="center"><em>- Ended Q2 2026 with cash position of $149 million, runway into 2028 -</em></p> <p>LEXINGTON, Mass., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today reported second quarter 2026 financial and operating results.</p> <p>“We view tau as a critical disease-modifying target in Alzheimer’s disease, and we believe recent third-party data validate this hypothesis,” said Alfred W. Sandrock, Jr., M.D., Ph.D., Chief Executive Officer of Voyager. http://www.streetinsider.com/Press+Releases/Voyager+Reports+Second+Quarter+2026+Financial+and+Operating+Results/26883252.html Thu, 06 Aug 2026 16:01:00 -0400 A.00556501 A.06822034 A.09642568 A.17150087 O.00222524 O.17919569 O.20026344 O.20371933 O.34929518 VYGR http://www.streetinsider.com/Globe+Newswire/Voyager+Reports+Second+Quarter+2026+Financial+and+Operating+Results/26883252.html <p align="center"><em>- VY7523 clinical data and VY1706 clinical entry, both in Alzheimer’s, expected Q4 2026 -</em></p> <p align="center"><em>- Ended Q2 2026 with cash position of $149 million, runway into 2028 -</em></p> <p>LEXINGTON, Mass., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today reported second quarter 2026 financial and operating results.</p> <p>“We view tau as a critical disease-modifying target in Alzheimer’s disease, and we believe recent third-party data validate this hypothesis,” said Alfred W. Sandrock, Jr., M.D., Ph.D., Chief Executive Officer of Voyager. http://www.streetinsider.com/Globe+Newswire/Voyager+Reports+Second+Quarter+2026+Financial+and+Operating+Results/26883252.html Thu, 06 Aug 2026 16:01:00 -0400 A.00556501 A.06822034 A.09642568 A.17150087 O.00222524 O.17919569 O.20026344 O.20371933 O.34929518 VYGR http://www.streetinsider.com/Globe+Newswire/Voyager+Reports+Second+Quarter+2026+Financial+and+Operating+Results/26883252.html <p align="center"><em>- VY7523 clinical data and VY1706 clinical entry, both in Alzheimer’s, expected Q4 2026 -</em></p> <p align="center"><em>- Ended Q2 2026 with cash position of $149 million, runway into 2028 -</em></p> <p>LEXINGTON, Mass., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today reported second quarter 2026 financial and operating results.</p> <p>“We view tau as a critical disease-modifying target in Alzheimer’s disease, and we believe recent third-party data validate this hypothesis,” said Alfred W. Sandrock, Jr., M.D., Ph.D., Chief Executive Officer of Voyager. http://www.streetinsider.com/Globe+Newswire/Voyager+Reports+Second+Quarter+2026+Financial+and+Operating+Results/26883252.html Thu, 06 Aug 2026 16:01:00 -0400 A.00556501 A.06822034 A.09642568 A.17150087 O.00222524 O.17919569 O.20026344 O.20371933 O.34929518 VYGR http://www.streetinsider.com/Globe+Newswire/Voyager+Reports+Second+Quarter+2026+Financial+and+Operating+Results/26883252.html <p align="center"><em>- VY7523 clinical data and VY1706 clinical entry, both in Alzheimer’s, expected Q4 2026 -</em></p> <p align="center"><em>- Ended Q2 2026 with cash position of $149 million, runway into 2028 -</em></p> <p>LEXINGTON, Mass., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today reported second quarter 2026 financial and operating results.</p> <p>“We view tau as a critical disease-modifying target in Alzheimer’s disease, and we believe recent third-party data validate this hypothesis,” said Alfred W. Sandrock, Jr., M.D., Ph.D., Chief Executive Officer of Voyager. http://www.streetinsider.com/Globe+Newswire/Voyager+Reports+Second+Quarter+2026+Financial+and+Operating+Results/26883252.html Thu, 06 Aug 2026 16:01:00 -0400 A.00556501 A.06822034 A.09642568 A.17150087 O.00222524 O.17919569 O.20026344 O.20371933 O.34929518 VYGR http://www.streetinsider.com/Globe+Newswire/Voyager+Reports+Second+Quarter+2026+Financial+and+Operating+Results/26883252.html <p align="center"><em>- VY7523 clinical data and VY1706 clinical entry, both in Alzheimer’s, expected Q4 2026 -</em></p> <p align="center"><em>- Ended Q2 2026 with cash position of $149 million, runway into 2028 -</em></p> <p>LEXINGTON, Mass., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today reported second quarter 2026 financial and operating results.</p> <p>“We view tau as a critical disease-modifying target in Alzheimer’s disease, and we believe recent third-party data validate this hypothesis,” said Alfred W. Sandrock, Jr., M.D., Ph.D., Chief Executive Officer of Voyager. http://www.streetinsider.com/Globe+Newswire/Voyager+Reports+Second+Quarter+2026+Financial+and+Operating+Results/26883252.html Thu, 06 Aug 2026 16:01:00 -0400 A.00556501 A.06822034 A.09642568 A.17150087 O.00222524 O.17919569 O.20026344 O.20371933 O.34929518 VYGR http://www.streetinsider.com/Globe+Newswire/Voyager+Reports+Second+Quarter+2026+Financial+and+Operating+Results/26883252.html <p align="center"><em>- VY7523 clinical data and VY1706 clinical entry, both in Alzheimer’s, expected Q4 2026 -</em></p> <p align="center"><em>- Ended Q2 2026 with cash position of $149 million, runway into 2028 -</em></p> <p>LEXINGTON, Mass., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today reported second quarter 2026 financial and operating results.</p> <p>“We view tau as a critical disease-modifying target in Alzheimer’s disease, and we believe recent third-party data validate this hypothesis,” said Alfred W. Sandrock, Jr., M.D., Ph.D., Chief Executive Officer of Voyager. http://www.streetinsider.com/Globe+Newswire/Voyager+Reports+Second+Quarter+2026+Financial+and+Operating+Results/26883252.html Thu, 06 Aug 2026 16:01:00 -0400 A.00556501 A.06822034 A.09642568 A.17150087 O.00222524 O.17919569 O.20026344 O.20371933 O.34929518 VYGR http://www.streetinsider.com/Globe+Newswire/Voyager+Reports+Second+Quarter+2026+Financial+and+Operating+Results/26883252.html <p align="center"><em>- VY7523 clinical data and VY1706 clinical entry, both in Alzheimer’s, expected Q4 2026 -</em></p> <p align="center"><em>- Ended Q2 2026 with cash position of $149 million, runway into 2028 -</em></p> <p>LEXINGTON, Mass., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today reported second quarter 2026 financial and operating results.</p> <p>“We view tau as a critical disease-modifying target in Alzheimer’s disease, and we believe recent third-party data validate this hypothesis,” said Alfred W. Sandrock, Jr., M.D., Ph.D., Chief Executive Officer of Voyager. http://www.streetinsider.com/Globe+Newswire/Voyager+Reports+Second+Quarter+2026+Financial+and+Operating+Results/26883252.html Thu, 06 Aug 2026 16:01:00 -0400 A.00556501 A.06822034 A.09642568 A.17150087 O.00222524 O.17919569 O.20026344 O.20371933 O.34929518 VYGR http://www.streetinsider.com/Globe+Newswire/Voyager+Reports+Second+Quarter+2026+Financial+and+Operating+Results/26883252.html <p align="center"><em>- VY7523 clinical data and VY1706 clinical entry, both in Alzheimer’s, expected Q4 2026 -</em></p> <p align="center"><em>- Ended Q2 2026 with cash position of $149 million, runway into 2028 -</em></p> <p>LEXINGTON, Mass., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today reported second quarter 2026 financial and operating results.</p> <p>“We view tau as a critical disease-modifying target in Alzheimer’s disease, and we believe recent third-party data validate this hypothesis,” said Alfred W. Sandrock, Jr., M.D., Ph.D., Chief Executive Officer of Voyager. http://www.streetinsider.com/Globe+Newswire/Voyager+Reports+Second+Quarter+2026+Financial+and+Operating+Results/26883252.html Thu, 06 Aug 2026 16:01:00 -0400 A.00556501 A.06822034 A.09642568 A.17150087 O.00222524 O.17919569 O.20026344 O.20371933 O.34929518 VYGR